StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
22nd Century Group Trading Down 9.8 %
Shares of XXII stock opened at $0.23 on Thursday. The stock has a 50 day moving average of $0.48 and a 200 day moving average of $4.07. The stock has a market cap of $1.89 million, a P/E ratio of 0.00 and a beta of 1.41. 22nd Century Group has a twelve month low of $0.22 and a twelve month high of $16.00.
22nd Century Group (NASDAQ:XXII – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.36) EPS for the quarter. The business had revenue of $7.95 million during the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%.
Hedge Funds Weigh In On 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Articles
- Five stocks we like better than 22nd Century Group
- Business Services Stocks Investing
- CarMax’s Impressive Rally: What Investors Should Watch Next
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 9/23 – 9/27
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.